



MID AND SOUTH ESSEX MEDICINES OPTIMISATION COMMITTEE (MSEMOC)

CRISABOROLE FOR TREATING MILD TO MODERATE ATOPIC DERMATITIS IN PEOPLE 2 YEARS AND OLDER, NICE TA701, MAY 2021 (TERMINATED APPRAISAL)

BLACK: NOT RECOMMENDED FOR PRESCRIBING IN PRIMARY, COMMUNITY OR SECONDARY CARE

Mid and South Essex CCGs do not support the prescribing of crisaborole for treating mild to moderate atopic dermatitis in people 2 years and older in accordance with local recommendations for all drugs with a terminated NICE technology appraisal.

[NICE TA701](#) guidance:

NICE is unable to make a recommendation on crisaborole for treating mild to moderate atopic dermatitis in people 2 years and older because Pfizer withdrew its evidence submission. NICE will review this decision if the company decides to make a submission.

Providers commissioned to provide services on behalf of Mid and South Essex CCGs are reminded that they are required to follow the local joint formulary and prescribing guidance, as detailed in the medicines management service specification of their contract.

References	NICE TA701: Crisaborole for treating mild to moderate atopic dermatitis in people 2 years and older: https://www.nice.org.uk/guidance/ta701
Acknowledgements	Mid and South Essex CCGs Medicines Management Teams
Version	1.0
Author	HCPMSEMOC working group
Approved by	MSEMOC
Date Approved	July 2021
Review Date	July 2026 or sooner if subject to any new updates nationally